SCHEMBL655203

SCHEMBL655203

Cc1cc(OC2CCN(C)C2)ccc1N=NC=c1[nH]c(=O)c(=Cc2cnc(N3CCCCC3)s2)s1

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.34
BTK Q06187 6/20 0.33
ALDH1A1 P00352 1/20 0.32
CHEK1 O14757 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL655202 0.85 PARP1 (0.33) PARP1BTK
SCHEMBL655205 0.85 PARP1 (0.33) PARP1BTK
SCHEMBL708157 0.82 SYK (0.35) PARP1ALDH1A1
SCHEMBL10176550 0.79 MAPT (0.40) PARP1
SCHEMBL651185 0.79 MAPT (0.40) PARP1
SCHEMBL252929 0.72 PARP1 (0.34) PARP1
SCHEMBL252930 0.72 PARP1 (0.34) PARP1
SCHEMBL252931 0.72 PARP1 (0.34) PARP1
SCHEMBL701907 0.71 KDM4E (0.37) PARP1
SCHEMBL701908 0.71 KDM4E (0.37) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 PARP1 4100/4885BTK 1014/4885ALDH1A1 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.